Tamoxifen and endometrial carcinoma: Alterations in estrogen and progesterone receptors in untreated patients and combination hormonal therapy in advanced neoplasia

1984 ◽  
Vol 17 (2) ◽  
pp. 262
Author(s):  
John A. Carlson ◽  
Joseph C. Allegra ◽  
Thomas G. Day ◽  
James L. Wittliff
2003 ◽  
Vol 121 (4) ◽  
pp. 163-166 ◽  
Author(s):  
Vera Lúcia Leite Bonfitto ◽  
Liliana Aparecida Lucci de Angelo Andrade

CONTEXT: Diagnostic staging is an important prognostic factor for endometrial adenocarcinoma. Apart from the histological type and histological grade, some markers seem to be associated with the stage and biological behavior of the disease. Among these are p53, estrogen and progesterone receptors. OBJECTIVE: The objectives of the present study were: to compare histological type and grading of endometrial carcinoma in curettage and hysterectomy samples; to assess expression of p53, estrogen and progesterone receptors in curettage specimens; and to correlate these data with morphology and staging of the disease in hysterectomy specimens. TYPE OF STUDY: Retrospective. SETTING: Department of Pathology, Faculdade de Ciências Médicas, Universidade Estadual de Campinas. SAMPLE: Histological diagnosis from 51 consecutive files. PROCEDURES: Immunohistochemical reactions for p53, estrogen and progesterone receptors via the avidin-biotin-peroxidase method in 51 curettage samples endometrial carcinoma were compared with the morphological data and disease stage in hysterectomy. Marker expression was correlated with histological type and grade and the final stage of the disease. RESULTS: According to the histological type: 44 cases (86%) were of endometrioid and 7 (14%) non-endometrioid carcinoma. p53 expression was observed in 16% of endometrioid and 71% of non-endometrioid cases (p < 0.05). Although estrogen expression was more evident in endometrioid (54%) than non-endometrioid cases (29%), this was not statistically significant. Progesterone receptor expression was significantly higher in endometrioid than non-endometrioid cases (70% vs. 14%, p < 0.05). According to the histological grade: Estrogen and progesterone receptors were expressed more frequently in grade I endometrioid carcinoma, while p53 was mainly reported in tumor grades II and III. According to final disease stage: p53 and estrogen expression in curettage specimens was not related to stage; progesterone receptors, however, were expressed significantly less in advanced disease. CONCLUSION: p53 was observed in the majority of non-endometrioid and in high-grade endometrioid carcinoma, but was not related to stage. Estrogen and progesterone receptors were mainly found in grade I endometrioid carcinoma. The markers studied in curettage were no more valuable for predicting the disease stage than classical histological criteria.


1993 ◽  
Vol 12 (3) ◽  
pp. 246-252 ◽  
Author(s):  
Henrik G. J. Nyholm ◽  
Anette L. Nielsen ◽  
Jens Lyndrup ◽  
Anne Dreisler ◽  
Susan M. Thorpe

2017 ◽  
Vol 1 ◽  
pp. 228-235 ◽  
Author(s):  
Luis Fernando Méndez-López ◽  
Angel Zavala-Pompa ◽  
Elva I. Cortés-Gutiérrez ◽  
Ricardo M. Cerda-Flores ◽  
Martha I. Davila-Rodriguez

2020 ◽  
pp. 74-77
Author(s):  
Waziha Ahmed ◽  
Geetanjali Gogoi ◽  
Sabari Devi

The endometrium which lines the uterine cavity is one of the most dynamic tissues in the human body. Proliferation and differentiation of the endometrial glands and stroma are regulated by steroid hormones mainly estrogen and progesterone. Endometrial hyperplasia is a heterogeneous set of pathologic lesions that range from mild, reversible glandular proliferations to direct cancer precursors. Endometrial carcinoma is one of the most common gynecologic malignancies in industrialized and developing countries and is generally accepted to be an endocrine related neoplasm. Understanding the biochemical basis of endometrial responsiveness to hormones in such patients is fundamental to designing a successful medical therapy. The estrogen receptor (ER) and progesterone receptor (PR) are measured by biochemical and immunohistochemical methods . Immunohistochemistry (IHC) is a semiquantitative method for determination of protein expression. The technique is inexpensive and relatively quick to perform. Immunohistochemistry was done in this study to evaluate the expression of ER, PR in cases of Endometrial hyperplasia and Endometrial Carcinoma. A total of 42 cases were evaluated immunohistochemically which included 32 cases of Non atypical hyperplasia, 7 cases of Atypical hyperplasia and 3 cases of Endometrial carcinoma. The expression of ER/PR was maximal for cases of Non atypical hyperplasia, followed by atypical hyperplasia and least for endometrial carcinoma. Those can be benefited from hormonal therapy, especially atypical hyperplasia cases, whose progression can be halted by hormonal therapy.


Sign in / Sign up

Export Citation Format

Share Document